Ipatasertib / GDC-0068

Target: AKT | Disease State: Solid Tumors

Introduction / Brief Description

Ipatasertib is an AKT inhibitor invented by Array under a collaboration agreement with Genentech. Array has received certain clinical milestones and is entitled to additional potential clinical and commercial milestones and royalties on product sales under the agreement.

AKT activity is frequently elevated in cancer via multiple mechanisms, including loss of function of the PTEN tumor suppressor gene or mutations/amplifications of the PIK3CA or AKT genes. AKT pathway activation is associated with poor prognosis and may lead to resistance to chemotherapy. Ipatasertib is advancing in clinical development, including two Phase 3 trials in patients with prostate cancer or breast cancer and multiple Phase 2 trials in patients with breast cancer, gastric cancer and prostate cancer.

Clinical Trials

To learn more about ipatasertib clinical trials, click here.

Publications and Presentations

Ipatasertib

10/14/2012

International Society for the Study of Xenobiotics North American Regional Meeting

Preclinical ADME Evaluation of GDC-0068, a Novel, ATP-competitive Akt Inhibitor

B. M. Liederer, et al

Ipatasertib

09/28/2012

European Society for Medical Oncology Congress

Phase Ib Dose Escalation Study of the Akt Inhibitor GDC-0068 with Docetaxel or mFOLFOX6 in Patients with Advanced Solid Tumors

J.C. Bendell, et al.

Ipatasertib

08/30/2012

Journal of Medicinal Chemistry

Discovery and Preclinical Pharmacology of a Selective ATP-Competitive Akt Inhibitor (GDC-0068) for the Treatment of Human Tumors

J. F. Blake, et al.

These compounds and their uses are investigational and have not been approved by the U.S. Food and Drug Administration. This information is presented only for purposes of providing a general overview of our clinical trials only.